Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
GeoVision Inc
TWSE:3356
|
TW |
|
O
|
Ourpalm Co Ltd
SZSE:300315
|
CN |
|
P
|
Peninsula Group Ltd
TASE:PEN
|
IL |
|
Geberit AG
SIX:GEBN
|
CH |
|
Camden Property Trust
NYSE:CPT
|
US |
|
HanseYachts AG
XETRA:H9Y
|
DE |
|
N
|
NextGen Healthcare Inc
F:QY1
|
US |
|
B
|
Benara Bearings and Pistons Ltd
BSE:541178
|
IN |
|
H
|
Himalaya Shipping Ltd
OSE:HSHIP
|
BM |
|
Better Collective A/S
STO:BETCO
|
DK |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
|
14B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
865.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
577.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.5B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.6B USD |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Yipinhong Pharmaceutical Co Ltd
Glance View
Yipinhong Pharmaceutical Co Ltd has carved its niche in the pharmaceutical landscape of China, with its roots embedded deeply in the nation's flourishing healthcare sector. Known for its dedication to combining traditional Chinese medicinal practices with modern scientific research, the company stands out in an increasingly competitive market. Yipinhong's operations are centered around developing, manufacturing, and distributing a broad spectrum of medicinal products that adhere to the highest quality standards. By focusing on therapeutic areas such as respiratory, cardiovascular, and gastrointestinal health, they strategically align with the growing demand for reliable medicinal solutions. What makes Yipinhong truly distinctive is its investment in research and development that drives innovation. This focus not only ensures a continuous pipeline of new products but positions them as a leader in the integration of traditional remedies with cutting-edge pharmaceutical science. The company thrives on a business model that maximizes its robust distribution network, encompassing both domestic and international markets. Yipinhong capitalizes on its vast network of sales agents and partnerships with hospitals, clinics, and pharmacies to ensure its products reach consumers efficiently. This network amplifies their revenue streams by tapping into various segments within the pharmaceutical supply chain. Moreover, Yipinhong's strategic collaborations for research and development and their participation in healthcare industry events bolster their market presence and brand recognition. By maintaining a harmonious balance between traditional approaches and modern demands, Yipinhong not only captures a unique market position but also sets a benchmark in pharmaceutical excellence and innovation.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Yipinhong Pharmaceutical Co Ltd is -53.4%, which is below its 3-year median of -7.1%.
Over the last 3 years, Yipinhong Pharmaceutical Co Ltd’s Operating Margin has decreased from 11.4% to -53.4%. During this period, it reached a low of -53.4% on Oct 30, 2025 and a high of 15.2% on Mar 31, 2023.